Drugs / Gonadorelin
Gonadorelin
also known as
GnRH · gonadotropin-releasing hormone · gonadorelin acetate · ABBOTT-41070 · AY-24,031 · Factrel · Fertagyl · Fertiral lh-rh · +17 more
Protein / enzyme biologic targets GNRHR via activation
Regulatory milestones approvals, filings & regulatory actions · 1 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Approved | US (FDA) | FACTREL | — | 1982-09-30 | fda.gov ↗ |
Trials 19
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 18 trials | ||||||
| Phase 1 | NCT05901467 | Oct 2023 → May 2024 | reproductive system disorder | Massachusetts General Hospital | Terminated | No outcome recorded |
| Phase 1 | NCT03142893 | May 2017 → Oct 2020 overdue | — | Peter y. Liu | Active not recruiting | No outcome recorded |
| Phase 1 | NCT01952782 | Apr 2014 → May 2016 | hypogonadotropic hypogonadism | Massachusetts General Hospital | Completed | No outcome recorded |
| Phase 1 | NCT01438034 | Jun 2013 → Sep 2019 | Kallmann syndrome | Massachusetts General Hospital | Completed | No outcome recorded |
| Phase 1 | NCT01438073 | Sep 2011 → Apr 2016 | gonadal agenesis, hypogonadotropic hypogonadism | Massachusetts General Hospital | Completed | No outcome recorded |
| Phase 1 | NCT00914823 | Jun 2009 → Oct 2021 | Kallmann syndrome, hyperprolactinemia, polycystic ovary syndrome | Massachusetts General Hospital | Completed | No outcome recorded |
| Phase 1 | NCT00493961 | Jan 1999 → Nov 2009 | Kallmann syndrome | Massachusetts General Hospital | Completed | No outcome recorded |
| Phase 1 | NCT00392756 | Apr 1989 → May 2019 | Kallmann syndrome | Massachusetts General Hospital | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT02956447 | Nov 2017 → Jun 2023 | hyperprolactinemia, hypogonadism | Massachusetts General Hospital | Completed | No outcome recorded |
| Phase 2 | NCT00383656 | Jan 1989 → Sep 2020 | Kallmann syndrome, amenorrhea | Massachusetts General Hospital | Unknown | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT00386022 | Jan 2002 → Jan 2012 | — | Massachusetts General Hospital | Unknown | No outcome recorded |
| Phase 31 trial · 1 met primary | ||||||
| Phase 3 | NCT01976728 | Apr 2014 → Feb 2018 | hypogonadotropic hypogonadism | Ferring Pharmaceuticals | Completed | Met primary |
| Phase 41 trial | ||||||
| Phase 4 | NCT03989024 | Jul 2019 → Dec 2020 | anovulation, infertility disorder, polycystic ovary syndrome | RenJi Hospital | Unknown | No outcome recorded |
| Phase not applicable6 trials | ||||||
| — | NCT05184374 | Jan → Jun 2022 | hypogonadotropic hypogonadism | Huashan Hospital | Unknown | No outcome recorded |
| — | NCT02653092 | Jun 2016 → Dec 2023 overdue | hyperinsulinism, hypogonadotropic hypogonadism, infertility disorder, obesity disorder | University of Colorado, Denver | Active not recruiting | No outcome recorded |
| — | NCT02705014 | Jan → Aug 2016 | hypogonadotropic hypogonadism | Peking Union Medical College Hospital | Unknown | No outcome recorded |
| — | NCT00392457 | Jul 1995 → Feb 2007 | Kallmann syndrome | Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | Completed | No outcome recorded |
| — | NCT00004426 | Aug 1994 → Sep 1998 | hypogonadism | University of Chicago | Completed | No outcome recorded |
| — | NCT00004330 | Mar 1987 → ? | porphyria | National Center for Research Resources (NCRR) | Completed | No outcome recorded |
| Comparator or background therapy5 trials | ||||||
| Phase 0 | NCT04037605 Background | Feb 2020 → Jul 2022 overdue | — | Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center | Active not recruiting | No outcome recorded |
| Phase 1 | NCT00431197 Background | Feb 2004 → Dec 2007 | hypogonadism | Mayo Clinic | Completed | No outcome recorded |
| Phase 2 | NCT04648969 Background | May 2019 → Aug 2025 | hypogonadotropic hypogonadism | Massachusetts General Hospital | Completed | No outcome recorded |
| Phase 2 | NCT00064987 Background | Apr 2001 → Oct 2012 | Kallmann syndrome | Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2/3 | NCT04390646 Comparator | Aug 2020 → Dec 2028 expected | Down syndrome, early-onset autosomal dominant Alzheimer disease, olfactory nerve disorder | Nelly Pitteloud | Recruiting | No outcome recorded |
Press releases naming this drug 1 release
Evidence & citations 31 cited values
Every value below carries the sentence it was read from. 28 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Gonadorelin | “pulse infusion of gonadorelin via micropump” PMID 25131486 ↗ Aug 2014 |
| Known as | ABBOTT-41070 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1007 ↗ |
| Known as | AY-24,031 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1007 ↗ |
| Known as | Factrel | ChEMBL registry synonym — accepted as the source's own label CHEMBL1007 ↗ |
| Known as | Fertagyl | ChEMBL registry synonym — accepted as the source's own label CHEMBL1007 ↗ |
| Known as | Fertiral lh-rh | ChEMBL registry synonym — accepted as the source's own label CHEMBL1007 ↗ |
| Known as | GnRH | “pulsatile GnRH therapy in IHH men is very successful in inducing androgen production and spermatogenesis” PMID 12213860 ↗ Sep 200214“gonadotropin releasing hormone (GnRH)” NCT00493961 ↗ “gonadotropin releasing hormone (GnRH)” NCT00064987 ↗ |
| Known as | gonadorelin acetate | “GnRH, gonadorelin acetate” NCT04390646 ↗ |
| Known as | Gonadorelin acetate anhydrous | ChEMBL registry synonym — accepted as the source's own label CHEMBL1007 ↗ |
| Known as | Gonadorelin acetate mixture | ChEMBL registry synonym — accepted as the source's own label CHEMBL1007 ↗ |
| Known as | Gonadorelin decapeptide | ChEMBL registry synonym — accepted as the source's own label CHEMBL1007 ↗ |
| Known as | Gonadorelin hcl | ChEMBL registry synonym — accepted as the source's own label CHEMBL1007 ↗ |
| Known as | GONADORELIN HYDROCHLORIDE | ChEMBL registry synonym — accepted as the source's own label CHEMBL1007 ↗ |
| Known as | Gonadorelina | ChEMBL registry synonym — accepted as the source's own label CHEMBL1007 ↗ |
| Known as | Gonadoreline | ChEMBL registry synonym — accepted as the source's own label CHEMBL1007 ↗ |
| Known as | gonadotropin-releasing hormone | “two investigational drugs, the naturally occurring hormones kisspeptin and gonadotropin-releasing hormone (GnRH)” NCT01438034 ↗6“Drug: Gonadotropin-releasing Hormone” NCT02705014 ↗ |
| Known as | Hypocrine | ChEMBL registry synonym — accepted as the source's own label CHEMBL1007 ↗ |
| Known as | Lh releasing factor | ChEMBL registry synonym — accepted as the source's own label CHEMBL1007 ↗ |
| Known as | Luteinizing | ChEMBL registry synonym — accepted as the source's own label CHEMBL1007 ↗ |
| Known as | luteinizing hormone-releasing factor | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00004330 ↗ |
| Known as | Luteinizing hormone-releasing factor diacetate tetrahydrate | ChEMBL registry synonym — accepted as the source's own label CHEMBL1007 ↗ |
| Known as | Luteinizing hormone-releasing factor dihydrochloride | ChEMBL registry synonym — accepted as the source's own label CHEMBL1007 ↗ |
| Known as | Lutrelef | ChEMBL registry synonym — accepted as the source's own label CHEMBL1007 ↗ |
| Known as | Lutrepulse | “Gonadorelin (also known as Lutrepulse)” NCT04037605 ↗ |
| Known as | Lutrepulse kit | ChEMBL registry synonym — accepted as the source's own label CHEMBL1007 ↗ |
| Known as | Relefact lh-rh | ChEMBL registry synonym — accepted as the source's own label CHEMBL1007 ↗ |
| Action | Restore | “This treatment replaces the hormone which is absent in IHH” NCT00392756 ↗ |
| Modality | Peptide | “Although differences in plasma GnRH concentrations have been identified after iv and sc injection of this peptide” PMID 3900124 ↗ Nov 1985 |
| Modality | Protein / enzyme biologic | — CHEMBL1007 ↗ |
| Route | Subcutaneous | “Patients receive one subcutaneous injection of leuprolide acetate or GnRH” NCT00004426 ↗ |
| Target | GNRHR | “Pulsatile GnRH acts on the gonadotrophs via the GnRH receptor (GNRHR) in the pituitary gland” NCT04390646 ↗ |